Aim. The aim of this review is to provide recommendations on the use of hydrolysates in infants when formula feeding is initiated.
INTRODUCTION
In healthy infants and in infants with high risk for developing allergy, exclusive breastfeeding for about 6 months is a desirable goal. Hydrolyzed formulas contain cow milk proteins (CMPs) that are subjected to chemical and enzymatic hydrolysis to reduce the molecular weight, the peptide size, and consequently, the allergenicity of the proteins. The differentiation between extensively hydrolyzed and partially hydrolyzed formulas is generally done by i) molecular weight profile and ii) clinical demonstration of reduced allergenicity.
The protein molecular weight profile is an analytical classification measure that offers a straightforward differentiation between intact, partially and extensively hydrolyzed protein formulas (1) . The methods use molecular weight markers that enable to qualify and quantify the proteins/peptides as % of total protein. The most important protein fractions present in cow milk (whey, casein) are used for the hydrolysis process rather than whole CMP (2) .
Whole cow milk-based formulas contain proteins in the range of 14 kD (α-lactalbumin) to 67 kD (bovine serum albumin). Partially hydrolyzed formulas (pHF) contain reduced oligopeptides that have a molecular weight of generally less than 5 kD (ranges between 3 kD and 10 kD); and peptides in extensively hydrolysed formula (eHFs) have, in >90%, a molecular weight of <3 kD (2, 3) . Both pHFs and eHFs consist of a wide range of peptide sizes. Protein molecular weight profile only enables to differentiate the protein characteristics of formulas, but does not determine the allergenic formula properties. Moreover, there is no regulatory definition of eHFs and pHFs.
In addition, commercially available whey pHF (pHF-W)contain 18% of peptides greater than 6 kD, while eHFs contain between 1% and 5% greater than 3.5 kD. Peptides need to be in the range of 10 kD to 70 kD (predominantly 10 kD to 40 kD) to be able to act as an allergen (4,5).
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The degree of hydrolysis may be characterized by biochemical techniques, such as the spectrum of peptide molecular weights or the ratio of alpha amino nitrogen to total nitrogen (6) . Assuming the theory that the shorter the peptides, the less allergenic the product, much work has been done to determine the molecular weight of residual peptides in the hydrolysates (7) . As a practical guideline for the industry, the appropriate cutoff for the absence of larger peptides has been determined to be approximately 1.5 kD (7).
The term "hypoallergenicity" or "HA" does not have a globally uniform interpretation. In the European Union, the term is associated with the health claim "Reduction of risk to allergy to milk protein" as defined by "Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC". eHFs comply with the above conditions too and are also "HA". However, these are used for "the dietary management of cow milk allergy". In the USA the term "HA" is a health claim that requires premarket approval by FDA (similar in Canada). Basically only eHFs are considered "HA" and thus can be used for the dietary management of CMPA. Because the wording "hypoallergenicity", abbreviated as "HA", does have such a different meaning in different parts of the world, we should no longer use the wording "hypoallergenic" in scientific papers to avoid confusion, but rather use "partial" or "extensive" hydrolysates.
Despite the evidence available, there is still uncertainty regarding the choice, if at all, of a hydrolyzed formula in the feeding of infants as well as uncertainty regarding the actual efficacy to prevent allergy of a particular formula. Efficacy and safety should be established especially for cow milk protein hydrolyzed formulas, as factors such as the protein source, hydrolysis method, and degree of hydrolysis that often depend on the manufacturer contribute to differences among hydrolysates.
While acknowledging that breast feeding is the recommended feeding for infants with and without risk of developing allergy (3, 8) , the authors joined forces to provide recommendations on the use of hydrolysates in infants when formula feeding is initiated.
The objective of this statement was i) to systematically review and update data on the efficacy and safety of using a CMP hydrolyzed formula of any degree of hydrolysis compared with a standard infant formula in reducing the risk of allergy in healthy infants at high risk for allergy or in those without a risk; ii) to formulate recommendations.
METHODS
An overview of reviews followed by a systematic review of subsequently published trials was carried out. The guidelines from the Cochrane Collaboration for overview of reviews, as well as comments by Smith et al. (9) , were followed for the overview of reviews. All relevant systematic reviews/meta-analyses of randomized controlled trials (RCTs) and quasi-RCTs were considered for inclusion. The participants in the included trials had to be infants at high risk of developing allergy, as assessed by a family history (the presence of allergy in at least one parent and/or sibling) and/or other markers (as determined by the study investigators), or without any risk. The included trials compared use of formulas based on cow milk protein hydrolysates with standard infant formula or follow-on formula. The primary outcomes of interest in included trials were those related to allergic disease such as all allergic diseases, including atopic eczema/atopic dermatitis, gastrointestinal symptoms, food allergy/hypersensitivity, respiratory symptoms (wheezing and/or asthma), allergic rhinitis, and urticaria (if reported together); atopic eczema/atopic dermatitis; respiratory symptoms (wheezing, asthma as diagnosed by a physician), allergic rhinitis, food allergy/hypersensitivity, urticaria, and anaphylaxis. Search methods are outlined in the onlineonly appendix (http://links.lww.com/MPG/A301).
RESULTS

Overview of reviews
Eight systematic reviews with or without a meta-analysis met the inclusion criteria (Alexander questioned (18) , thus, these reviews were excluded. Two reviews (Foisy et al (14) ., Osborn & Sinn 2007(15) (17) ) and methodological quality of the reviews are described in Tables 1 & 2 . Both the reviews of 
Hydrolyzed formulas and allergy risk:
The Cochrane Review (15) showed that compared to human milk feeding, feeding a hydrolyzed formula (all types) from birth onwards during the first few days of life in low risk infants resulted in no significant difference in infant allergy or childhood cow milk allergy (CMA). Compared to cow milk formula, there was no benefit of short-term feeding (average four days) of a hydrolyzed formula (all types). One large quasi-RCT reported a reduction in infant CMA of borderline significance in low-risk infants
(1 RCT, n=3473; RR 0.62, 95% CI 0.38, 1.00). Compared to standard cow milk formula, prolonged (in the first four to six months of life) feeding with a hydrolyzed formula (all types) in high-risk infants resulted in a significant reduction in infant allergy (7 RCTs, n=2514 infants; RR 0.79, 95% CI 0.66, 0.94) and a significant reduction in CMA (1 RCT, n=67; RR 0.36, 95% CI 0.15, 0.89). The duration of intervention in the "long-term" prevention studies was four to six months; the different reviews define this as "prolonged feeding". There were no significant differences between groups in the incidence of childhood
Copyright © ESPGHAN and NASPGHAN. All rights reserved. For all allergic diseases (7 RCTs), using a random-effects model, use of pHF-W was statistically significantly more effective in reducing the risk of all allergic diseases (incidence) compared with standard formula at 3 to 6 months (5 RCTs, RR 0.48, 95% CI 0.23 to 1.00), at For atopic dermatitis or atopic eczema (8 RCTs), using a random-effects model, the use of pHF compared with standard formula statistically significantly reduced the incidence of eczema at one year (4 RCTs; RR 0.68, 95% CI 0.48 to 0.98; I2=0%), but not at 4 to 6 months (5 RCTs), 2 years (3 RCTs), nor 30 to 36 months (2 RCTs).
There were no statistically significant differences between pHF-W and eHF-W nor eHF-C formula in the risk reduction for all allergic diseases nor for atopic dermatitis or atopic eczema. Sensitivity analyses did not significantly alter these results.
